Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:DTIL NASDAQ:GNTA NASDAQ:KPTI NASDAQ:LPTX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeDTILPrecision BioSciences$5.44+0.4%$4.89$3.61▼$9.81$64.12M1.7293,050 shs85,337 shsGNTAGenenta Science$3.24-2.3%$3.43$2.56▼$7.28$60.36M0.5814,150 shs6,864 shsKPTIKaryopharm Therapeutics$6.38+1.4%$5.82$3.51▼$16.95$55.32M0.3494,966 shs47,255 shsLPTXLeap Therapeutics$0.53-26.9%$0.33$0.22▼$4.79$22.11M-0.052.01 million shs6.98 million shsThe Best High-Yield Dividend Stocks for 2025Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceDTILPrecision BioSciences0.00%+7.51%+8.15%+24.34%-40.55%GNTAGenenta Science0.00%+4.15%-7.57%-16.39%-27.63%KPTIKaryopharm Therapeutics0.00%-2.60%-5.34%+38.10%-51.88%LPTXLeap Therapeutics0.00%+52.43%+88.72%+85.24%-78.22%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeDTILPrecision BioSciences$5.44+0.4%$4.89$3.61▼$9.81$64.12M1.7293,050 shs85,337 shsGNTAGenenta Science$3.24-2.3%$3.43$2.56▼$7.28$60.36M0.5814,150 shs6,864 shsKPTIKaryopharm Therapeutics$6.38+1.4%$5.82$3.51▼$16.95$55.32M0.3494,966 shs47,255 shsLPTXLeap Therapeutics$0.53-26.9%$0.33$0.22▼$4.79$22.11M-0.052.01 million shs6.98 million shsThe Best High-Yield Dividend Stocks for 2025Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceDTILPrecision BioSciences0.00%+7.51%+8.15%+24.34%-40.55%GNTAGenenta Science0.00%+4.15%-7.57%-16.39%-27.63%KPTIKaryopharm Therapeutics0.00%-2.60%-5.34%+38.10%-51.88%LPTXLeap Therapeutics0.00%+52.43%+88.72%+85.24%-78.22%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceDTILPrecision BioSciences 2.33Hold$47.00763.97% UpsideGNTAGenenta Science 1.00SellN/AN/AKPTIKaryopharm Therapeutics 2.50Moderate Buy$34.00432.92% UpsideLPTXLeap Therapeutics 1.75Reduce$3.38532.61% UpsideCurrent Analyst Ratings BreakdownLatest LPTX, DTIL, GNTA, and KPTI Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/27/2025DTILPrecision BioSciencesWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)9/27/2025GNTAGenenta ScienceWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)9/27/2025KPTIKaryopharm TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)9/27/2025LPTXLeap TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)8/12/2025KPTIKaryopharm TherapeuticsRobert W. BairdSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOutperform$42.00 ➝ $25.007/16/2025KPTIKaryopharm TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy ➝ Neutral7/11/2025KPTIKaryopharm TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$27.00(Data available from 10/5/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookDTILPrecision BioSciences$68.70M0.93N/AN/A$6.87 per share0.79GNTAGenenta ScienceN/AN/AN/AN/A$0.74 per shareN/AKPTIKaryopharm Therapeutics$145.24M0.38N/AN/A($22.10) per share-0.29LPTXLeap TherapeuticsN/AN/AN/AN/A$0.91 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateDTILPrecision BioSciences$7.17M-$8.810.00N/AN/A-6,205.79%-176.47%-69.05%11/3/2025 (Estimated)GNTAGenenta Science-$9.64MN/A0.00N/AN/AN/AN/AN/AN/AKPTIKaryopharm Therapeutics-$76.42M-$14.59N/AN/AN/A-90.02%N/A-84.28%11/4/2025 (Estimated)LPTXLeap Therapeutics-$67.56M-$1.580.00N/AN/AN/A-237.65%-155.38%11/12/2025 (Estimated)Latest LPTX, DTIL, GNTA, and KPTI EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/14/2025Q2 2025LPTXLeap Therapeutics-$0.29-$0.40-$0.11-$0.40N/AN/A8/11/2025Q2 2025KPTIKaryopharm Therapeutics-$3.80-$4.32-$0.52-$4.32$37.92 million$37.93 million8/7/2025Q2 2025DTILPrecision BioSciences-$0.09-$2.13-$2.04-$2.13$6.27 million$0.02 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthDTILPrecision BioSciencesN/AN/AN/AN/AN/AGNTAGenenta ScienceN/AN/AN/AN/AN/AKPTIKaryopharm TherapeuticsN/AN/AN/AN/AN/ALPTXLeap TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioDTILPrecision BioSciences0.665.185.18GNTAGenenta ScienceN/AN/AN/AKPTIKaryopharm TherapeuticsN/A0.990.94LPTXLeap TherapeuticsN/A1.341.34Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipDTILPrecision BioSciences37.99%GNTAGenenta Science15.13%KPTIKaryopharm Therapeutics66.44%LPTXLeap Therapeutics30.46%Insider OwnershipCompanyInsider OwnershipDTILPrecision BioSciences4.00%GNTAGenenta Science28.99%KPTIKaryopharm Therapeutics2.75%LPTXLeap Therapeutics7.50%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableDTILPrecision BioSciences20011.79 million11.32 millionNo DataGNTAGenenta Science718.29 million12.99 millionNot OptionableKPTIKaryopharm Therapeutics3808.67 million8.43 millionOptionableLPTXLeap Therapeutics4041.44 million38.33 millionOptionableLPTX, DTIL, GNTA, and KPTI HeadlinesRecent News About These CompaniesLeap Therapeutics to Present Final Clinical Data from Part B of the DeFianCe Study at the ESMO Congress 2025September 25, 2025 | prnewswire.comLeap Therapeutics Reports Q2 2025 Financial ResultsAugust 15, 2025 | msn.comLeap Therapeutics, Inc.: Leap Therapeutics Reports Second Quarter 2025 Financial ResultsAugust 14, 2025 | finanznachrichten.deLeap Therapeutics Reports Second Quarter 2025 Financial ResultsAugust 14, 2025 | prnewswire.comLeap Therapeutics, Inc. (LPTX) - Yahoo FinanceJuly 5, 2025 | finance.yahoo.comLeap Therapeutics Initiates Process To Explore Strategic OptionsJune 24, 2025 | nasdaq.comLeap Slashes 75% of Workforce, Explores Strategic OptionsJune 24, 2025 | biospace.comBLeap Therapeutics Reports Updated Clinical Data from Sirexatamab Colorectal Cancer Study and Announces Exploration of Strategic AlternativesJune 23, 2025 | prnewswire.comLeap Therapeutics, Inc.: Leap Therapeutics Reports First Quarter 2025 Financial ResultsMay 13, 2025 | finanznachrichten.deLeap halves head count, narrows lead cancer drug's focus amid 'difficult market environment'May 13, 2025 | fiercebiotech.comFLeap Therapeutics Reports First Quarter 2025 Financial ResultsMay 13, 2025 | prnewswire.comLeap Therapeutics to Present Preclinical Data of FL-501, a Novel GDF-15 Neutralizing Antibody, at the AACR 2025 Annual MeetingApril 25, 2025 | prnewswire.comLeap Therapeutics to Host Virtual KOL Event to Discuss Sirexatamab (DKN-01) in Second-line Patients with Advanced Microsatellite Stable Colorectal CancerApril 15, 2025 | prnewswire.comLeap Therapeutics (LPTX) Conference Call to discuss Updated Data from Part B of the DeFianCe Study TranscriptMarch 31, 2025 | seekingalpha.comH.C. Wainwright Reaffirms Their Hold Rating on Leap Therapeutics (LPTX)March 27, 2025 | markets.businessinsider.comLeap Therapeutics, Inc.: Leap Therapeutics Reports Positive Updated Data from Sirexatamab Colorectal Cancer StudyMarch 26, 2025 | finanznachrichten.deLeap Therapeutics, Inc.: Leap Therapeutics Reports Fourth Quarter and Full Year 2024 Financial ResultsMarch 26, 2025 | finanznachrichten.deLeap Therapeutics Reports Fourth Quarter and Full Year 2024 Financial ResultsMarch 26, 2025 | prnewswire.comLeap Therapeutics Reports Positive Updated Data from Sirexatamab Colorectal Cancer StudyMarch 26, 2025 | prnewswire.comLeap Therapeutics downgraded to Neutral from Buy at H.C. WainwrightJanuary 29, 2025 | markets.businessinsider.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeLPTX, DTIL, GNTA, and KPTI Company DescriptionsPrecision BioSciences NASDAQ:DTIL$5.44 +0.02 (+0.37%) Closing price 10/3/2025 04:00 PM EasternExtended Trading$5.31 -0.13 (-2.46%) As of 10/3/2025 07:35 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Precision BioSciences, Inc., an advanced gene editing company, develops in vivo gene editing therapies for gene edits, including gene elimination, insertion, and excision in the United States. The company offers ARCUS, a genome editing platform to DNA genome insertion, deletion, and repair. It also provides PBGENE-HBV for the treatment of chronic hepatitis B virus (HBV) to eliminate covalently closed circular DNA with direct cuts and edits as well as to inactivate integrated HBV DNA with the goal of long-lasting reductions in hepatitis B surface antigen; PBGENE-PMM for the treatment of m.3243 associated primary mitochondrial myopathy (PMM) which is expected to submit an IND and/or CTA. In addition, it develops PBGENE-NVS for sickle cell disease/beta thalassemia for insertion; PBGENE-DMD (excision) for duchenne muscular dystrophy; PBGENE-LL2 (insertion), a liver directed target; PBGENE-LL3, a central nervous system directed target; and iECURE-OTC (insertion) for ornithine transcarbamylase deficiency. The company has license and collaboration agreement with Caribou Biosciences, Inc.; license agreement with TG Cell Therapy, Inc. to develop, manufacture, and commercialize azer-cel for autoimmune diseases and other indications outside of cancer; development and license agreement with Eli Lilly and Company for the research and development of potential in vivo therapies for genetic disorders; Cellectis S.A.; iECURE, Inc. to develop ARCUS-based gene-insertion therapies; Duke University; and Novartis Pharma AG to discover and develop in vivo gene editing products. Precision BioSciences, Inc. was incorporated in 2006 and is headquartered in Durham, North Carolina.Genenta Science NASDAQ:GNTA$3.24 -0.08 (-2.27%) As of 10/3/2025 04:00 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Genenta Science S.p.A., a clinical-stage biotechnology company, engages in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors in Italy. Its lead product candidate is Temferon, which is in Phase 1/2a clinical trials for use in the treatment of glioblastoma multiforme in patients with unmethylated MGMT gene promoter. The company is developing Temferon for use in the treatment of other solid tumor indications, locally advanced hepatocellular carcinoma, and intra-hepatic cholangiocarcinoma. In addition, it develops biologic platform to deliver immunomodulatory molecules directly to the tumor by infiltrating monocytes/macrophages. Genenta Science S.p.A. was incorporated in 2014 and is headquartered in Milan, Italy.Karyopharm Therapeutics NASDAQ:KPTI$6.38 +0.09 (+1.43%) Closing price 10/3/2025 04:00 PM EasternExtended Trading$6.46 +0.08 (+1.25%) As of 10/3/2025 07:52 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1). Its lead compound, include XPOVIO in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma; in combination with dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma; and for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). It also developing Selinexor for treating hematological and solid tumor malignancies, including multiple myeloma, endometrial cancer, myelofibrosis, and DLBCL; and ELTANEXOR for treating Myelodysplastic Neoplasms, as well as verdinexor, KPT-9274, and IL-12 compounds. The company has license agreement with Menarini Group to develop and commercialize selinexor for human oncology indications; license agreement with Antengene Therapeutics Limited to develop and commercialize selinexor, eltanexor, and KPT-9274 for the treatment and/or prevention of human oncology indications, as well as verdinexor for the diagnosis, treatment, and/or prevention of human non-oncology indications; and distribution agreement for the commercialization of XPOVIO with FORUS Therapeutics Inc. Further, it has a collaboration with Bristol Myers Squibb company to evaluate novel cereblon E3 ligase modulator agent mezigdomide in combination with Selinexor in patients with relapsed/refractory multiple myeloma. Karyopharm Therapeutics Inc. was incorporated in 2008 and is headquartered in Newton, Massachusetts.Leap Therapeutics NASDAQ:LPTX$0.53 -0.20 (-26.92%) Closing price 10/3/2025 04:00 PM EasternExtended Trading$0.56 +0.02 (+4.40%) As of 10/3/2025 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Leap Therapeutics, Inc., a biopharmaceutical company, acquires and develops antibody therapies for the treatment of cancer. Its lead product candidates include DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in multiple ongoing clinical trials for treating esophagogastric and gynecologic cancers; and FL-301, a monoclonal antibody that targets cells that express Claudin18.2 on their cell surface and is in phase II clinical trial, as well as two preclinical antibody programs, FL-302 and FL-501. Leap Therapeutics, Inc. has an option and license agreement with NovaRock, Adimab, and BeiGene, Ltd. to develop and commercialize DKN-01 in Asia (excluding Japan), Australia, and New Zealand. The company was formerly known as HealthCare Pharmaceuticals, Inc. and changed its name to Leap Therapeutics, Inc. in November 2015. Leap Therapeutics, Inc. was incorporated in 2011 and is based in Cambridge, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Cheap Chipotle? Why CMG Stock Could Be Ready for a Comeback Alphabet: After Its Best Quarter in Decades, Is It Time to Buy? After Trump Deal, Can Meta Stock Withstand TikTok’s Onslaught? Starbucks Stock Slumps; This Competitor Shows Strength How Berkshire's OxyChem Buy Cements Its Long-Term Strength The Trade Desk: 2 Signs of a Comeback, 1 Risk Ahead NVIDIA Breaks Out to New Highs: What Comes Next? Down 22% From Highs, ServiceNow Could Be Too Cheap to Ignore Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
